ENLV Share Price | Enlivex Therapeutics Ltd. Stock Analysis & Recommendation

Q: What does Enlivex Therapeutics Ltd. do?

Overview:Enlivex Therapeutics Ltd. is an Israel-based clinical-stage company focused on specialized cell immunotherapy within the Pharmaceuticals & Biotechnology industry, aiming to develop an allogeneic drug pipeline for rebalancing immune hyper-responses.Financial Snapshot:Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 24.57 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -69.45% Price to Book: 1.19 Contact Details:Address: 14 Einstein St., NESS-ZIONA None: 7403618 Tel: 972 2 6708072 Fax: 972 2 6708070 Website: https://www.enlivex.com/

Q: Is Enlivex Therapeutics Ltd. technically bullish or bearish?

As of 18 August 2025, the technical trend for Enlivex Therapeutics Ltd. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness, while the weekly MACD is mildly bearish and the Bollinger Bands are bearish. The KST shows bullishness on both weekly and monthly time frames, which adds some strength to the mildly bullish outlook. However, the overall performance has been poor compared to the S&P 500, with a year-to-date return of -10.26% versus the S&P 500's 12.22%, and a one-year return of -32.26% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

40.88 k

Shareholding (Dec 2025)

FII

0.37%

Held by 8 FIIs

DII

99.36%

Held by 1 DIIs

Promoter

0.00%

How big is Enlivex Therapeutics Ltd.?

22-Jun-2025

As of Jun 18, Enlivex Therapeutics Ltd. has a market capitalization of 24.57 million and reported net sales of 0.00 million with a net profit of -14.33 million over the last four quarters. Shareholder's funds are 23.59 million, and total assets amount to 27.69 million.

View full answer

What does Enlivex Therapeutics Ltd. do?

22-Jun-2025

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage company specializing in cell immunotherapy to develop treatments for immune hyper-responses. It has a market cap of $24.57 million and reported a net loss of $3 million in Q1 2025.

View full answer

Who are in the management team of Enlivex Therapeutics Ltd.?

22-Jun-2025

As of March 2022, the management team of Enlivex Therapeutics Ltd. includes Executive Chairman Mr. Shai Novik and Directors Mr. Michel Habib, Mr. Baruch Halpert, Dr. Bernhard Kirschbaum, Dr. Hyun Gyu Lee, and Mr. Sangwoo Lee.

View full answer

Is Enlivex Therapeutics Ltd. technically bullish or bearish?

20-Sep-2025

As of August 18, 2025, Enlivex Therapeutics Ltd. shows a mildly bullish trend, supported by daily moving averages and KST indicators, despite underperforming the S&P 500 with year-to-date and one-year returns of -10.26% and -32.26%, respectively.

View full answer

Compare Enlivex Therapeutics Ltd. with Similar Stocks

Unity Biotechnology, Inc.Alaunos Therapeutics, Inc.Co-Diagnostics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 256 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-72.66%

Price to Book

14.67

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

1,243 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.77%

6 Months

-19.69%

1 Year

-23.51%

2 Years

-49.17%

3 Years

-70.69%

4 Years

-81.24%

5 Years

-92.0%

Enlivex Therapeutics Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-18.35%

EBIT to Interest (avg)

-12.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

13.72%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

14.67

EV to EBIT

-16.30

EV to EBITDA

-16.63

EV to Capital Employed

-238.33

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-72.66%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.27%)

Foreign Institutions

Held by 8 Foreign Institutions (0.37%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 24,005.77% vs 42.86% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.80",
          "val2": "-5.40",
          "chgp": "-7.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1,632.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,243.10",
          "val2": "-5.20",
          "chgp": "24,005.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8,336.67% vs 48.45% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.70",
          "val2": "-15.00",
          "chgp": "2.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1,632.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,235.50",
          "val2": "-15.00",
          "chgp": "8,336.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.80

-5.40

-7.41%

Interest

0.00

Exceptional Items

1,632.40

0.00

Consolidate Net Profit

1,243.10

-5.20

24,005.77%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 24,005.77% vs 42.86% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.70

-15.00

2.00%

Interest

0.00

Exceptional Items

1,632.40

0.00

Consolidate Net Profit

1,235.50

-15.00

8,336.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 8,336.67% vs 48.45% in Dec 2024

All Annual Results

Company CV

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd.

Pharmaceuticals & Biotechnology

Enlivex Therapeutics Ltd is an Israel-based clinical-stage company focused on specialized cell immunotherapy. The Company aims to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. The Company is developing Allocetra, a cell-based immunotherapy, for the treatment of numerous acute conditions. It rebalances a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms. Allocetra is designed to avert cytokine storms and restores safe immune balance, without suppressing the immune system, by engaging macrophages and dendritic cells. The Company’s clinical development programs focus on preventing or treating complications associated with bone-marrow transplantations, Sepsis and solid tumors.

Company Coordinates

Company Details

14 Einstein St. , NESS-ZIONA None : 7403618

Tel: 972 2 6708072

https://www.enlivex.com/

Registrar Details